On Wednesday, Liquidia got an upgrade to its Relative Strength (RS) Rating, from 68 to 75.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating identifies technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves. See if Liquidia can continue to rebound and hit that benchmark.
While Liquidia is not near an ideal entry right now, see if it manages to form and break out of a proper consolidation.
The company reported 0% earnings growth in its most recent report. Sales gains came in at 5%.
The company earns the No. 266 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
